TransCode Therapeutics (NASDAQ: RNAZ), a clinical-stage company developing immuno-oncology and RNA-based therapeutics for high-risk and advanced cancers, announced that a poster featuring its lead therapeutic candidate, TTX-MC138, will be presented at the European Society for Medical Oncology (ESMO) Congress 2026 on Oct. 23 in Madrid, Spain. The presentation will highlight the latest clinical update from the Phase 1a trial evaluating TTX-MC138 in patients with advanced solid tumors.
The ESMO Congress is one of the most influential gatherings in oncology, drawing researchers, clinicians, and industry leaders from around the world. Presenting updated Phase 1a data at this venue provides TransCode with a significant opportunity to showcase its technology to a global audience of key opinion leaders and potential partners. For a clinical-stage company, such visibility can be instrumental in building credibility and attracting interest in its pipeline.
TTX-MC138 is an investigational therapeutic designed to target miR-10b, a microRNA associated with metastatic disease progression. By inhibiting miR-10b, TransCode aims to address a fundamental driver of metastasis, which is responsible for the majority of cancer-related deaths. The Phase 1a trial is evaluating the safety, tolerability, and preliminary efficacy of TTX-MC138 in patients with advanced solid tumors, and the updated data could provide early signals of the drug’s potential.
The announcement is important because it signals that TransCode is advancing its lead candidate through clinical development and is prepared to share new findings with the scientific community. Positive or encouraging data could support further clinical trials and potentially accelerate the path toward regulatory approval. Conversely, the presentation may also reveal challenges that could inform the company’s next steps. Investors and industry observers will be watching closely for any signs of clinical benefit or biomarker activity.
TransCode’s approach is part of a broader effort to develop RNA-based therapies for cancer. The company’s portfolio includes other first-in-class therapeutic candidates designed to mobilize the immune system to recognize and destroy cancer cells. The upcoming presentation at ESMO Congress 2026 will be a key milestone for TransCode, as it seeks to differentiate its platform in a crowded oncology landscape.
For more information about TransCode Therapeutics, visit its investor page. The full press release can be accessed at this link, and the latest news and updates relating to RNAZ are available in the company’s newsroom at https://nnw.fm/RNAZ.
NetworkNewsWire, a specialized communications platform focused on financial news and content distribution, published the announcement. It is part of the Dynamic Brand Portfolio at IBN, which offers services including InvestorWire wire distribution and editorial syndication to 5,000+ outlets. Readers should review the full terms of use and disclaimers on the NetworkNewsWire website.
